Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Fix the driver behind crashes, sound loss and screen glitches3Clear out junk files and repair common Windows errorsProfluent is the startup behind OpenCRISPR-1, a Cas9-like gene editor designed with a protein-language-model AI. Its April 22, 2024 results showed editing in cultured human cells, not in a person. OpenCRISPR-1 is a research technology, not an approved treatment or consumer product.
The startup is Profluent, but the headline needs a qualifier
Profluent described OpenCRISPR-1 as the first gene-editing system whose components were fully designed by AI. The experiment involved human cells in a laboratory. It did not edit a human being’s genome, and it did not demonstrate a therapy that patients can receive.
How AI designed OpenCRISPR-1
Mining CRISPR diversity
Profluent assembled a CRISPR-Cas Atlas containing 5.1 million CRISPR-Cas proteins and trained a protein language model on that collection. The model generated millions of candidate protein sequences; researchers then selected candidates for laboratory testing.
A substantially different Cas9-like protein
OpenCRISPR-1 is reported to be more than 400 mutations away from the commonly used SpCas9 editor. Profluent says the modeling approach expanded the modeled diversity of CRISPR families by 4.8-fold.
What the experiment actually showed
The reported work used plasmid delivery in HEK293T human cells. In that laboratory assay, OpenCRISPR-1 produced measurable target-site editing and showed lower off-target activity than SpCas9 under the company’s stated test conditions.
| Measure | OpenCRISPR-1 | SpCas9 comparator |
|---|---|---|
| On-target editing | 55.7% | 48.3% |
| Off-target editing | 0.32% | 6.1% |
These percentages are company-reported experimental results from 2024. They are not clinical efficacy, patient-safety, or regulatory outcomes, and they should not be read as proof that the editor is safer in every cell type or delivery format.
What remains unproven
- Genome-wide specificity: Profluent said broader specificity studies were still underway, so the reported off-target comparison does not establish that no important unintended edits occur elsewhere in the genome.
- Delivery: The evidence described plasmid delivery to cultured cells. It does not show that the editor can be delivered effectively to a patient’s target tissue.
- Ribonucleoprotein behavior: Profluent identified the editor’s behavior as a purified ribonucleoprotein complex as an area still under study.
- Durability and efficacy: There is no demonstrated clinical durability, therapeutic benefit, or dose suitable for patients in the cited results.
- Regulatory status: OpenCRISPR-1 is not presented as an approved medicine or a clinical service.
Can people get OpenCRISPR-1 as a treatment?
No. The reported work is preclinical and limited to laboratory cell experiments. OpenCRISPR-1 is described as available under a license for ethical research and commercial use, while Profluent invites custom gene-editor collaborations. That is access for research and development partners, not a prescription, clinic procedure, or consumer product.
How safe is an AI-designed CRISPR editor?
AI can search sequence space far faster than conventional trial-and-error design, but speed does not remove the biological risks. Any candidate editor still requires testing for unintended edits, delivery to the correct cells, immune or toxic effects, persistence, manufacturing quality, and ethical use.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →Human oversight is therefore essential. Stanford’s report on CRISPR-GPT described safeguards that warn and halt requests involving virus or human-embryo editing. Stanford assistant professor Le Cong said, “The hope is that CRISPR-GPT will help us develop new drugs in months, instead of years.” He also framed the appeal—and the risk of acceleration—with the question, “Trial and error is often the central theme of training in science. But what if it could just be trial and done?” Those safeguards concern an AI research system, not proof that OpenCRISPR-1 itself is clinically safe.
A separate 2025 AI-and-CRISPR partnership
On March 10, 2025, ElevateBio announced a collaboration with AWS to apply generative AI to CRISPR therapeutic discovery and protein optimization through Life Edit. That institutional partnership indicates growing investment in AI-assisted gene-editing research, but it is separate from OpenCRISPR-1 and does not make Profluent’s editor clinically available.
Rank #4
- Investigate the building blocks of life and learn the ABC's of DNA!
- Isolate plant DNA in a test tube.
- Learn about biological inheritance.
- Assemble a DNA model to see its elegant double-stranded helical structure.
- A 48-page, full-color manual guides you through 20 experiments and teaches about the basics of genetics and DNA.
How to evaluate future AI gene-editing claims
- Check whether AI designed the editing molecule itself or only planned experiments.
- Separate results in cultured cells from animal studies and human trials.
- Look for the exact on-target assay, cell type, delivery method, and comparator.
- Ask whether off-target testing was targeted or genome-wide.
- Check evidence for delivery, durability, manufacturing, and clinical benefit.
- Verify licensing, regulatory status, and biosafety safeguards before treating a research announcement as a product.
The accurate takeaway
Profluent used AI to design OpenCRISPR-1 and reported editing human cells in the laboratory. That is a significant demonstration of AI-assisted protein design, but it is not the same as editing a person, proving a clinical treatment, or establishing long-term safety.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
